the Influence of General Anesthesia on Tumor Metastasis and Recurrence
1 other identifier
observational
300
1 country
1
Brief Summary
The purpose of this study was to investigate whether general anesthesia will affect the postoperative recurrence and metastasis of malignant tumor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
June 14, 2015
CompletedFirst Posted
Study publicly available on registry
June 17, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2019
CompletedJune 17, 2015
June 1, 2015
3 years
June 14, 2015
June 16, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Number of participants with tumor recurrence and metastasis
Follow-up of patients with tumor recurrence and metastasis after Radiofrequency ablation to 3 years
3 years
Study Arms (2)
general anesthesia
In this group，the patient is received radiofrequency ablation under general anesthesia.
local anesthesia
In this group，the patient is received radiofrequency ablation under local anesthesia.
Interventions
the patient received generalanesthesia and local anesthesia randomly
Eligibility Criteria
the patient with primary liver cancer.
You may qualify if:
- ASA I - III Primary liver cancer tumor is single and diameter is less than 3 centimeter There is no major vascular invasion phenomenon, no lymph nodes or extrahepatic metastases The Child - Pugh belong to type A or type B
You may not qualify if:
- Had a history of liver surgery (including radiofrequency ablation) Severe disease of heart, lung, kidney, the immune system INR \> 1.5 or platelet count is less than 45000 cells/mm3 History of opioid addiction Metastatic liver tumors Not sure of primary liver cancer Don't agree to participate in this experiment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RenJi Hospitallead
Study Sites (1)
Shanghai Renji Hospital
Shanghai, Shanghai Municipality, 200127, China
Biospecimen
blood
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 14, 2015
First Posted
June 17, 2015
Study Start
June 1, 2015
Primary Completion
June 1, 2018
Study Completion
April 1, 2019
Last Updated
June 17, 2015
Record last verified: 2015-06